Why the study?
Despite therapeutic advances, pulmonary arterial hypertension patients continue to experience high morbidity and mortality, prompting exploration of whether early, robust reduction of right ventricular afterload should be a treatment goal.
Does aggressive right ventricular afterload reduction improve right ventricular function and clinical outcomes in patients with pulmonary arterial hypertension?
Does aggressive right ventricular afterload reduction improve right ventricular function and clinical outcomes in patients with pulmonary arterial hypertension?
Aggressive afterload reduction using initial oral combination therapy and early parenteral prostanoids is proposed as a key treatment goal to improve right ventricular function and outcomes in pulmonary arterial hypertension.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for aggressive afterload reduction as PAH treatment goal; prospective trials needed to confirm RV benefits.
Vizza et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: